Business Wire

PROCESS-SYSTEMS-ENTERPRI

22.4.2016 16:46:03 CEST | Business Wire | Press release

Share
PSE: Advanced Process Modelling Forum Gathers Process Industries in London

At the 5th Advanced Process Modelling (APM) Forum in London this week, companies from across the process industries presented on topics ranging from accelerating development of the next generation of drugs to identifying hundreds of millions of Euros in operational savings in natural gas production.

Organised and hosted by Process Systems Enterprise (PSE), providers of the gPROMS APM platform, the two-day conference is a key event for process industry organisations focused on creating sustainable value through the application of high-accuracy predictive process modelling and optimisation.

In the sessions on formulated products, aimed at the pharmaceuticals, food & beverage, consumer goods and specialty chemicals sectors, presentations from AstraZeneca, Danone, Eli Lilly, Roche, Saint-Gobain, and Solvay described how new ‘digital design’ techniques are improving drug product manufacture, including development of robust continuous manufacturing processes, and accelerating time-to-market for new formulations.

A key event was the preview of PSE’s forthcoming gPROMS FormulatedProductsTM environment for integrated design and optimisation of formulated products and their manufacturing processes. Developed in co-operation with specialists from several sectors, this allows scientists and engineers to screen formulations for end-user attributes, determine whether they can be manufactured efficiently, and then use the gPROMS platform's optimisation capabilities to optimise the whole formulation and manufacturing chain.

In the oil & gas, chemicals, petrochemical & refining sessions, where presenters included Bharat Petroleum, BP Exploration, DSM, Primetals, SABIC, SCG Chemicals, Shell, Sulzer, Velocys and Yara International, the focus was on large-scale optimisation applications capable of improving profit by tens or hundreds of millions of Euros. These included major new developments in oilfield optimisation capable of identifying millions of dollars a day in increased production, Shell's work on region-wide optimisation of natural gas processing facilities, Bharat Petroleum’s innovative work in real-time optimisation of refinery crude transition, and DSM’s operational optimisation of the utility systems supplying electricity and steam to large-scale industrial sites. SABIC described how model-based analysis helped reduce the time to screen anti-coking technologies for ethylene production from years to months.

PSE MD Costas Pantelides said, “A key focus of the conference has been the coming of age of equation-oriented (EO) process modelling tools. EO is a disruptive technology that for the first time makes it possible to optimise large-scale, complex process systems using high-fidelity models and apply techniques such as global system analysis to explore the design and operational space much more rapidly than previously possible. This is enabling companies to realise large gains in competitive advantage and dramatically accelerate innovation”.

Keynote speaker Peter Drogt of DSM, standing in for Dorus van der Linden, said that advanced process modelling is crucial technology for the organisation to accelerate innovation and quantify process decisions. A key reason for the company’s move to APM is the ability to have a single unified modelling platform across the process lifecycle.

Editors: www.psenterprise.com/news/pr160422.html

Contact:

Process Systems Enterprise
Kate Burness
+44-20-8563-0888
k.burness@psenterprise.com

Link:

ClickThru

Social Media:

https://www.facebook.com/pages/Process-Systems-Enterprise-Limited-PSE/194030330653358?ref=bookmarks

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Tigo Energy Breaks Global Growth Benchmark; Boosts U.S. Energy Feature in Predict+4.5.2026 15:00:00 CEST | Press release

Advanced energy prediction platform adds real-time energy pricing for North American Independent System Operator (ISO) customers, accelerates meters-connected growth. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy solutions, today announced that the Predict+ platform now offers integrated real-time spot market pricing for ISO customers in the United States. Predict+ provides utilities with deep insights into grid demand, renewable generation, and energy market dynamics, enhancing the precision, scalability, and robustness of energy forecasting to up to 97.5% accuracy through machine learning and artificial intelligence. For energy providers, Predict+ helps streamline operations, reduce volatility, and maximize performance. Predict+ empowers utility operators to adapt to real-world demand challenges when balancing renewable and baseload generation sources, particularly during extreme weather events and market disruptions. On th

Airship Announces 2026 Elevate Customer Experience Award Winners4.5.2026 15:00:00 CEST | Press release

Southwest Airlines, The Economist, and OneFootball among brands recognized at Elevate’26 Customer Experience Summit for setting the standard in mobile-first and AI-centered customer experiences Airship, the mobile-first customer experience company, today announced the winners of the 2026 Elevate Customer Experience Awards. Global brand leaders from The Economist, Southwest Airlines, and OneFootball were among those honored at the Elevate’26 Customer Experience Summit. The Elevate Awards spotlight global companies that have developed exceptional mobile-first customer experiences for their customers, created innovative campaigns, leveraged AI agents to reach new levels of productivity, and achieved real business results. "Evolving mobile-first consumer behaviors and unprecedented advancements in AI are driving a seismic shift that is reshaping how brands interact with their customers," said Brett Caine, CEO, Airship. "The 2026 Elevate Award winners aren’t just adapting, they’re leading t

Alnylam to Present New Analyses at Heart Failure 2026 Underscoring Consistent Clinical Profile of Vutrisiran in ATTR-CM4.5.2026 14:30:00 CEST | Press release

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced it will present new data analyses for vutrisiran in patients with the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) at Heart Failure 2026, a scientific congress of the European Society of Cardiology, taking place May 9-12, 2026, in Barcelona, Spain. ATTR-CM is a heterogeneous and rapidly progressive disease, and patients often present with complex clinical profiles. At Heart Failure 2026, Alnylam will present multiple new analyses from the Phase 3 HELIOS-B study of vutrisiran, which continue to support its use as a first-line treatment for patients with ATTR-CM, and further characterize its clinical profile across patients with a high disease burden, and in the context of concomitant therapies. Vutrisiran is the first and only transthyretin (TTR) silencer for ATTR-CM that delivers rapid knockdown of TTR at the source. Additional analyses being pr

Takeda Announces Positive Topline Results from Pivotal Phase 2/3 Clinical Trial of TAK-881 in Primary Immunodeficiency Disease (PID)4.5.2026 14:00:00 CEST | Press release

Investigational TAK-881 was comparable to established HYQVIA while also demonstrating reduced infusion volume and duration for PID patients Takeda (TSE:4502/NYSE:TAK) today announced that TAK-881-3001, a pivotal Phase 2/3 clinical trial in patients with Primary Immunodeficiency Disease (PID), met its primary endpoint, which demonstrated pharmacokinetic (PK) comparability between the investigational TAK-881 [Immune Globulin Subcutaneous (Human), 20% Solution (SCIG 20%) with Recombinant Human Hyaluronidase] and HYQVIA [Immune Globulin Infusion (Human) 10% with Recombinant Human Hyaluronidase]. Additionally, secondary endpoints showed that TAK-881, a SCIG 20% facilitated with hyaluronidase, demonstrated safety, efficacy and tolerability profiles comparable to HYQVIA, an established SCIG 10% facilitated with hyaluronidase. These findings support the potential of TAK-881 to deliver the required immunoglobulin (IG) dose for PID patients in half the volume of HYQVIA, reducing infusion duratio

Ouster Releases The REV8 OS Family: The World’s First Native Color Lidar4.5.2026 12:00:00 CEST | Press release

Powered by the Company’s breakthrough L4 and L4 Max Ouster SiliconFeatures the first patented native color lidar sensors with point for point 3D color visionIntroduces flagship OS1 Max sensor with double the range and resolution of Rev7Auto-grade, cybersecure, and designed for functional-safety Ouster, Inc. (Nasdaq: OUST) (“Ouster” or the “Company”), a leader in sensing and perception for Physical AI, announced today its new family of OS digital lidar sensors, Rev8, powered by its next-generation L4 Ouster Silicon. Ouster Rev8 features the world’s first patented native color lidar sensors, provides up to double the range and resolution of the previous generation, and is designed for functional safety, reliability, affordability, and scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260504718668/en/ The REV8 OS Family: The World's First Native Color Lidar. L4 Ouster Silicon: Ouster’s breakthrough L4 architecture doubles t

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye